FDA Approves First New Class of Schizophrenia Medication in Decades
Federal regulators have approved a novel antipsychotic medication called Cobenfy, marking a significant shift from decades-old dopamine-targeting treatments.
❤️Conditions & CarePhoto: everydayhealth.com
Key points
- FDA approved Cobenfy capsules in September 2024 for adults with schizophrenia.
- It is the first muscarinic agonist, targeting cholinergic receptors instead of dopamine.
- Common side effects include nausea, indigestion, and elevated blood pressure, but it does not cause weight gain.
In September 2024, the U.S. Food and Drug Administration approved xanomeline and trospium chloride, marketed as Cobenfy capsules, for treating adult schizophrenia. According to reports from Everyday Health, this approval introduces the first new class of antipsychotic medications in decades. Unlike traditional treatments that focus primarily on brain dopamine pathways, this new muscarinic agonist targets cholinergic receptors to manage symptoms without typical weight gain side effects.
Clinical data highlights that while the medication avoids weight gain, it may bring other side effects such as nausea, indigestion, constipation, dizziness, and elevated blood pressure. Beyond pharmaceuticals, health guidelines emphasize comprehensive approaches like Coordinated Specialty Care—supported by the National Institute of Mental Health through the RAISE initiative—and electroconvulsive therapy for treatment-resistant symptoms.
What to know: Patients and caregivers are encouraged to learn about the condition and discuss personalized options with a qualified healthcare provider.
Source everydayhealth.com — everydayhealth.com/mental-health-conditions/schizophrenia-care/ ↗
Read next
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.